NO893021D0 - Fremgangsmaate for fremstilling av en biologisk aktiv forbindelse, fr 901228. - Google Patents

Fremgangsmaate for fremstilling av en biologisk aktiv forbindelse, fr 901228.

Info

Publication number
NO893021D0
NO893021D0 NO893021A NO893021A NO893021D0 NO 893021 D0 NO893021 D0 NO 893021D0 NO 893021 A NO893021 A NO 893021A NO 893021 A NO893021 A NO 893021A NO 893021 D0 NO893021 D0 NO 893021D0
Authority
NO
Norway
Prior art keywords
preparing
procedure
active compound
biological active
ferm
Prior art date
Application number
NO893021A
Other languages
English (en)
Other versions
NO893021L (no
Inventor
Masakuni Okuhara
Toshio Goto
Yasuhiro Hori
Takashi Fujita
Hirotsugu Ueda
Nobuharu Shigematsu
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10641100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO893021(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO893021D0 publication Critical patent/NO893021D0/no
Publication of NO893021L publication Critical patent/NO893021L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Reinforced Plastic Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO89893021A 1988-07-26 1989-07-25 Fremgangsmaate for fremstilling av en biologisk aktiv forbindelse, fr 901228. NO893021L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888817743A GB8817743D0 (en) 1988-07-26 1988-07-26 Fr901228 substance & preparation thereof

Publications (2)

Publication Number Publication Date
NO893021D0 true NO893021D0 (no) 1989-07-25
NO893021L NO893021L (no) 1990-01-29

Family

ID=10641100

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89893021A NO893021L (no) 1988-07-26 1989-07-25 Fremgangsmaate for fremstilling av en biologisk aktiv forbindelse, fr 901228.

Country Status (16)

Country Link
US (1) US4977138A (no)
EP (1) EP0352646B1 (no)
JP (1) JPH0764872B2 (no)
CN (1) CN1040054A (no)
AT (1) ATE94561T1 (no)
AU (1) AU3829089A (no)
CA (1) CA1335083C (no)
DE (1) DE68909139T2 (no)
DK (1) DK366889A (no)
ES (1) ES2058411T3 (no)
FI (1) FI893359A (no)
GB (1) GB8817743D0 (no)
HU (1) HU211514A9 (no)
IL (1) IL90949A0 (no)
NO (1) NO893021L (no)
ZA (1) ZA895121B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130414A (en) * 1989-11-30 1992-07-14 Arizona Board Of Regents, A Body Corporate Of Arizona State University Isolation and structural elucidation of the cyclic peptide hymenistatin 1
JPH06247964A (ja) * 1993-02-22 1994-09-06 Snow Brand Milk Prod Co Ltd 新規生理活性物質ｈｓ−１及びその製造方法
AU728202B2 (en) * 1996-11-22 2001-01-04 Pioneer Hi-Bred International, Inc. Moniliformin detoxification compositions and methods
JP3554707B2 (ja) * 1999-01-13 2004-08-18 山之内製薬株式会社 新規デプシペプチド化合物
US6828302B1 (en) 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
DE60033453T2 (de) * 1999-12-08 2007-11-29 Cyclacel Pharmaceuticals Inc. Verwendung von Depsipeptide und deren Analoge als Immunosuppressiva zur Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Allergien und hyperproliferativer Hautkrankheiten
DE60137932D1 (de) * 2000-07-17 2009-04-23 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
AU2001280109A1 (en) * 2000-09-01 2002-03-22 Fujisawa Pharmaceutical Co. Ltd. A method of producing fr901228
US8470783B2 (en) * 2001-08-21 2013-06-25 Astellas Pharma Inc. Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
AU2003219555A1 (en) * 2002-04-05 2003-10-20 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
MXPA05008904A (es) * 2003-02-19 2005-10-05 Astellas Pharma Inc Metodo para estimar el efecto antitumoral del inhibidor de desacetilasa de histona.
ES2397079T3 (es) * 2003-06-27 2013-03-04 Astellas Pharma Inc. Agente terapéutico para sarcoma de tejidos blandos
PL1670514T3 (pl) * 2003-09-25 2010-11-30 Astellas Pharma Inc Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
WO2005058298A2 (en) * 2003-12-10 2005-06-30 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20050261174A1 (en) * 2004-05-20 2005-11-24 Paul Lewer Insecticidal activity of a cyclic peptide
CA2586228A1 (en) * 2004-11-17 2006-05-26 The University Of Chicago Histone deacetylase inhibitors and methods of use
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
JP2009519224A (ja) * 2005-11-18 2009-05-14 グロスター ファーマシューティカルズ， インコーポレイテッド Ｈｄａｃインヒビターｆｋ２２８の代謝産物誘導体
US9539303B2 (en) * 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
WO2008083288A2 (en) * 2006-12-29 2008-07-10 Gloucester Pharmaceuticals Purifiction of romidepsin
AU2007342030B2 (en) 2006-12-29 2013-08-15 Celgene Corporation Romidepsin-based treatments for cancer
US8148102B2 (en) * 2007-02-08 2012-04-03 Uwm Research Foundation, Inc. Sequences for FK228 biosynthesis and methods of synthesizing FK228 and FK228 analogs
US20110060021A1 (en) * 2009-08-19 2011-03-10 Yiqiang Cheng Histone deacetylase inhibitors and uses thereof
AR080234A1 (es) 2010-02-25 2012-03-21 Marrone Bio Innovations Inc Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo
NZ605526A (en) 2010-07-12 2015-04-24 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
MX347407B (es) * 2011-08-27 2017-04-25 Marrone Bio Innovations Inc Cepa bacteriana aislada del genero burkholderia y metabolitos plaguicidas formulaciones derivadas de los mismos y usos.
CA2849708A1 (en) 2011-09-23 2013-03-28 Celgene Corporation Romidepsin and 5 - azacitidine for use in treating lymphoma
JP2014526564A (ja) 2011-09-26 2014-10-06 セルジーン コーポレイション 化学療法抵抗性癌の併用療法
US9963482B2 (en) 2011-09-30 2018-05-08 Tohoku University Phosphatidylinositol-3-kinase inhibitor and pharmaceutical composition
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
JP6170946B2 (ja) 2012-01-12 2017-07-26 セルジーン コーポレイション ロミデプシン製剤及びその使用
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN103877010B (zh) * 2012-12-21 2018-06-01 正大天晴药业集团股份有限公司 一种罗米地辛溶液的制备方法
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
WO2014134510A1 (en) 2013-02-28 2014-09-04 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
CN103173390B (zh) * 2013-03-16 2014-09-10 浙江海正药业股份有限公司 一种紫色杆菌菌株及其应用
CN104072589B (zh) * 2013-03-29 2017-09-22 浙江海正药业股份有限公司 抗肿瘤三硫化合物及其制备方法与应用
CN104450837B (zh) * 2013-09-18 2019-01-01 上海医药工业研究院 一种用于生产罗米地辛的方法及发酵培养基
CN104447950A (zh) * 2013-09-18 2015-03-25 上海医药工业研究院 一种罗米地辛的分离纯化方法
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
IN2014MU00740A (no) * 2014-03-04 2015-09-25 Concord Biotech Ltd
CN104894195B (zh) * 2014-03-07 2018-11-13 上海医药工业研究院 一种提高fk228产量的发酵培养基
CN104262456B (zh) * 2014-09-11 2018-01-09 浙江海正药业股份有限公司 一种罗米地辛的新晶型及其制备方法和用途
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
WO2017068596A1 (en) * 2015-10-20 2017-04-27 Msn Laboratories Private Limited An improved process for the preparation of (1s, 4s, 7z, 10s, 16e, 21r)- 7-ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5, 8, 20, 23- tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone
US20190119642A1 (en) 2016-03-15 2019-04-25 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
BR112021011370A2 (pt) 2018-12-14 2021-08-31 Pioneer Hi-Bred International, Inc. Produtos biológicos e seu uso em plantas
US20220049213A1 (en) * 2018-12-24 2022-02-17 Marrone Bio Innovations, Inc. A method for increasing romidepsin production from fermentation broth

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61101501A (ja) * 1984-10-24 1986-05-20 Yamanouchi Pharmaceut Co Ltd 制癌作用を有する多糖及びその製法
WO1986006065A1 (en) * 1985-04-18 1986-10-23 Pfizer Inc. Transformation product of thiosporamicin
DE3782199T2 (de) * 1986-07-08 1993-02-25 Takeda Chemical Industries Ltd Biologisch aktive peptide tan-866.
US4777160A (en) * 1986-09-18 1988-10-11 Bristol-Myers BU-2867T peptide antibiotics

Also Published As

Publication number Publication date
AU3829089A (en) 1990-02-01
EP0352646B1 (en) 1993-09-15
DK366889D0 (da) 1989-07-25
NO893021L (no) 1990-01-29
DE68909139T2 (de) 1994-02-10
CN1040054A (zh) 1990-02-28
IL90949A0 (en) 1990-02-09
CA1335083C (en) 1995-04-04
FI893359A0 (fi) 1989-07-11
ZA895121B (en) 1990-08-29
EP0352646A3 (en) 1990-10-31
FI893359A (fi) 1990-01-27
DK366889A (da) 1990-01-27
GB8817743D0 (en) 1988-09-01
JPH0285296A (ja) 1990-03-26
DE68909139D1 (de) 1993-10-21
US4977138A (en) 1990-12-11
ES2058411T3 (es) 1994-11-01
JPH0764872B2 (ja) 1995-07-12
EP0352646A2 (en) 1990-01-31
ATE94561T1 (de) 1993-10-15
HU211514A9 (en) 1995-11-28

Similar Documents

Publication Publication Date Title
NO893021D0 (no) Fremgangsmaate for fremstilling av en biologisk aktiv forbindelse, fr 901228.
DK551989D0 (da) 3-piperidinyl-1,2-benzisoxazoler, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende samme
DK0431350T3 (da) Ny polypeptidforbindelse og fremgangsmåde til fremstilling deraf
DK653688D0 (da) Stabiliserede laegemiddelaktive forbindelser, fremgangsmaade til deres frmstilling samt stabile laegemiddelpraeparater
HUT49113A (en) Process for producing 2-/2-hydroxy-3-phenoxy-propyl-amino/-ethyl-phenoxy-methyl-amido derivatives and pharmaceutical compositions containing them as active components
NO173444C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 4-(4'- fluorfenyl-)-tienopyridin-derivater
FI102547B1 (fi) Menetelmä valmistaa farmakologisesti käyttökelpoista peptidiyhdistettä
HUT51283A (en) Process for production of n-alkyl derivatives of bu-3608-antibiotics and medical compositions containing them as active substances
NO173991C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,2,5-ditiazocin-derivater
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
HUT47020A (en) Process for production of stabilly injectable medical compounds containing as active substance 1,4-dihidroxi-5,8-bis/2/2-hidroxi-ethil-amin/-ethil-amin-antraquinon-dihydrochlorid
ATE122352T1 (de) 3-(3-ethyl-1,2,4-oxadiazol-5-yl)-1- azabicycloheptan, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zubereitungen.
IT1229846B (it) Esteri di catecolammine.